CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Standard Public Health measuresWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug863 Treatment and prophylaxis Wiki 1.00
drug123 Biomarkers expression Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)

The investigators plan to evaluate the efficacy of the 'test and treat' strategy of infected patients and prophylactic chloroquine treatment to all contacts. The strategy entails decentralized COVID-19 testing and starting chloroquine treatment immediately in all who are found to be infected. As viral loads decline to undetectable levels, the probability of onward transmission is reduced to very low levels. Such evaluation will require prospective surveillance to assess the population-level effect of transmission prevention.

NCT04304053 COVID-19 Drug: Treatment and prophylaxis Other: Standard Public Health measures

Primary Outcomes

Description: Incidence of secondary cases among contacts of a case and contacts of contacts

Measure: Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases

Time: Up to 14 days after start of treatment

Secondary Outcomes

Measure: The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3

Time: 3 and 7 days after start of treatment

Measure: The mortality rate of subjects at weeks 2

Time: Up to 14 days after start of treatment

Measure: Proportion of participants that drop out of study

Time: Up to 14 days after start of treatment

Measure: Proportion of participants that show non-compliance with study drug

Time: Up to 14 days after start of treatment


No related HPO nodes (Using clinical trials)